Pulse oximetry: Lyla’s story

Born on 2 September 2015, Lyla Parry’s heart condition was finally detected when she was 11 days old and only when she was in heart failure. If pulse oximetry screening had been part of the routine newborn checks her condition could have been detected sooner. This is her story, as told by her mum, Janine Parry, … Continue reading “Pulse oximetry: Lyla’s story”

Coming closer to personalised head and neck cancer treatment

Can we predict how patients with head and neck cancers (HNC) will respond to different treatments based on their own gene signature? Researchers at BHP founder-member the University of Birmingham believe so,  and are s step closer to developing personalised medicine for HNC. Published in Clinical Cancer Research, the four-year study was led by experts in … Continue reading “Coming closer to personalised head and neck cancer treatment”

Diabetes research assesses effectiveness of diagnosis test

Diabetes consultants at BHP founder member University Hospitals Birmingham NHS Foundation Trust have found that the most common test for type 2 diabetes is less accurate for patients with some health conditions. The HbA1c test measures the sugar levels in people’s blood over the previous three months, with higher levels of blood glucose being a … Continue reading “Diabetes research assesses effectiveness of diagnosis test”

Birmingham endoscopy trials helping to improve patient outcomes

Two trials, led by the NIHR Birmingham Biomedical Research Centre’s Gastroenterology team, are leading to changes in the diagnosis and treatment for patients with inflammatory bowel conditions. The OPTIMA trial uses confocal laser endomicroscopy to detect a number of labelled  antibodies in patients, which acts as a reliable indicator for how well patients will respond … Continue reading “Birmingham endoscopy trials helping to improve patient outcomes”

Progress in new treatment for Idiopathic Intracranial Hypertension

An innovative new approach for treating patients with idiopathic intracranial hypertension (IIH) is on the way, following the flotation of a new company which will develop the treatment. Invex Therapeutics Ltd has commenced trading on the Australian Stock Exchange (ASX) following completion of a successful Initial Public Offering (IPO) to raise a $A12 million at … Continue reading “Progress in new treatment for Idiopathic Intracranial Hypertension”